ovarian cancer/fallopian tube cancer/primary peritoneal adenocarcinoma
Conditions
Interventions
Case series:chemotherapy and immunotherapy
Sponsors
Beijing Cancer Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. aged >=18 years; 2. histologically confirmed epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer.Types: non-specific adenocarcinoma (NOS), clear cell carcinoma, endometrioid adenocarcinoma, malignant brenner's tumor, mixed epithelial carcinoma, mucinous adenocarcinoma, serous adenocarcinoma, transitional cell carcinoma and undifferentiated carcinoma; 3. at least one measurable tumor lesion (according to RECIST1.1); 4. ECOG score 0-1; 5. the subject must have appropriate organ functions, and the results of the following laboratory tests were met before enrollment: 1) bone marrow reserve was basically normal: ANC>=1.5x10^9/L, HB>=90 g/L, PLT>=100x10^9/L; 2) liver function was basically normal: TBIL=60mL/min, calculated according to the cockroft-gault formula: male GFR=(140-age)*BW/(Scr*72), female GFR= male *0.85; 4) basically normal coagulation function: INR=12 weeks; 8. at least 4 weeks from the latest chemotherapy, and at least 4 half-life elution is required if anti-tumor biological products have been received; 9. toxic and side effects caused by previous treatment should be restored to <=level 1 (CTCAE5.0); 10. subject shall give informed consent to this study before the test and voluntarily sign a written informed consent; 11. the subject can communicate well with the researcher and complete the study according to the study regulations.
Exclusion criteria
Exclusion criteria: 1. age > 75 years old; 2. ECOG score >=2 points; 3. ovarian tumors with low malignant potential, such as borderline tumors; 4. the patient has other invasive malignant tumors (except non-melanoma skin cancer) or previous malignant tumor treatment is contraindicated in the current treatment regimen; 5. severe infections require intravenous antibiotics or hospitalization; 6. CNS disease unrelated to tumor, symptomatic brain metastasis; 7. complete intestinal obstruction; 8. sensitivity to Albumin-bound paclitaxel or sintilimab; 9. the patient has previously received immunotherapy, such as pd-1 antibody, pd-l1 antibody, CTLA4 antibody, etc. 10. used immunosuppressive drugs within 4 weeks, not including the nasal spray, inhalation, or other ways of topical corticosteroids or physiological doses of systemic corticosteroids (i.e., no more than 10 mg/day prednisone or other equivalent dose glucocorticoids), allowing for treatment of diseases such as asthma, chronic obstructive pulmonary disease, breathing difficulties for the temporary use of glucocorticoid.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor markers test;Target lesion; | — |
Countries
China
Contacts
Public ContactZheng Hong
Beijing Cancer Hospital
Outcome results
None listed